BriaCell Therapeutics Corp.

BCT

CA1079303071

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 01:10:01 15/07/2026 HKT			5-day change	1st Jan Change
5.230 ^CAD	-1.88%		+6.30%	-46.63%

07-07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
06-26	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI

Top Premarket Decliners

Published on 01/14/2026 at 08:57 pm HKT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about BriaCell Therapeutics Corp.

07-07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
06-26	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI
06-25	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company	MT
06-10	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-03	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering	MT
06-03	BriaCell Therapeutics Closes $4.7 Million Share Offering	MT
06-01	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting	MT
06-01	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million	MT
06-01	BriaCell Therapeutics Prices $4.7 Million Share Offering	MT
06-01	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share	RE
05-26	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer	CI
05-26	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study	MT
05-26	BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer	MT
05-26	Briacell receives positive recommendation from data safety monitoring board (DSMB) for phase 3 study in metastatic breast cancer	RE
05-22	BriaCell Says Presenting Posters, Publication-only Abstracts at ASCO 2026	MT

Chart BriaCell Therapeutics Corp.

Duration

Period

BCT: Dynamic Chart

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Employees

Sector

Biotechnology & Medical Research

More about the company